儿童耐药性癫痫长期生存:药物、迷走神经刺激与颅脑手术的比较
基于美国49家儿童医院行政数据库的观察性队列研究,纳入2004至2020年0-17岁耐药性癫痫患者,比较仅用抗癫痫药物、药物联合迷走神经刺激(VNS)及药物联合颅脑癫痫手术三种治疗方式的长期生存率。
要点
- 颅脑癫痫手术与VNS均与较药物治疗更高的长期生存率相关。
- 需多学科综合团队个体化评估药物与手术治疗选项。
核心结论
- 接受颅脑癫痫手术或VNS的儿童耐药性癫痫患者生存率高于仅接受药物治疗者。
研究设计与样本
- 观察性队列研究,使用美国儿科健康信息系统行政数据库,覆盖49家以上儿童医院。
- 纳入2004年1月1日至2020年12月31日诊断的0-17岁耐药性癫痫患者。
- 采用逆概率治疗加权(IPTW)平衡基线特征,加权Kaplan-Meier分析生存概率,加权Cox模型分析死亡风险。
主要发现
- 中位年龄:药物组7岁(IQR 4-12),VNS组9岁(IQR 6-13),手术组9岁(IQR 5-13)。
临床怎么用
- 对儿童耐药性癫痫应考虑多学科综合团队评估,个体化选择药物、VNS或颅脑手术。
- 手术和VNS可作为药物治疗之外改善长期生存的选项,需结合患者具体情况部署。
局限性
- 为观察性队列研究,基于行政数据库,可能存在未测量的混杂因素。
- 耐药性癫痫诊断依赖ICD编码,可能存在编码偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term survival in paediatric epilepsy is incompletely characterised. A better understanding of treatment effects on mortality in paediatric patients with drug-resistant epilepsy is needed for health-care decision making. We aimed to compare the long-term survival rates associated with antiseizure medications only, antiseizure medications plus vagus nerve stimulation (VNS), and antiseizure medications plus cranial epilepsy surgery in paediatric patients with drug-resistant epilepsy using a large national administrative database in the USA. METHODS: In this observational cohort study, patients aged 0-17 years who were diagnosed with drug-resistant epilepsy using International Classificiaton of Diseases codes between Jan 1, 2004, and Dec 31, 2020, were identified from the Pediatric Health Information System, an administrative database that contains inpatient, emergency department, ambulatory, and observation unit encounter-level data from more than 49 children's hospitals in the USA. Patients treated with at least three types of antiseizure medications were included in the medical therapy cohort, those treated with antiseizure medications plus VNS were included in the VNS cohort, and those treated with antiseizure medications plus cranial epilepsy surgery were included in the surgery cohort. Participants were followed up until the date of their last clinical encounter, in-hospital death, or Dec 31, 2020. Inverse probability of treatment weighting (IPTW) was used to balance baseline demographics and clinical characteristics between treatment groups. The unconditional probabilities of survival were estimated by weighted Kaplan-Meier analysis. A weighted Cox proportional hazards model was used to investigate the association between risk of overall death and age, sex, geographical region, race and ethnicity, comorbidity, primary diagnosis, insurance, and treatment. FINDINGS: This study included 10 240 patients treated with antiseizure medications only, 5019 patients treated with antiseizure medications plus VNS, and 3033 patients treated with antiseizure medications plus cranial epilepsy surgery. The median age of paediatric patients was 7 years (IQR 4-12) in the medical therapy cohort, 9 years (6-13) in the VNS cohort, and 9 years (5-13) in the surgery cohort. The IPTW-adjusted probabilities of surviving beyond 10 years were 89·27% (95% CI 87·71-90·85) for the medical therapy cohort, 92·65% (90·62-94·72) for the VNS cohort, and 98·45% (97·53-99·38) for the surgery cohort. The difference in survival probabilities was significant (log-rank p<0·0001). Compared with the medical therapy cohort, the IPTW-adjusted hazard ratio for overall death was 0·60 (95% CI 0·50-0·74) for the VNS cohort and 0·19 (0·10-0·33) for the surgery cohort. INTERPRETATION: Paediatric patients with drug-resistant epilepsy who underwent cranial epilepsy surgery or VNS had a higher survival rate than those who received only medical treatment. These findings highlight the importance of a multidisciplinary comprehensive team approach to the treatment of epilepsy, which includes tailored evaluation and deployment of medical and surgical treatment options for patients with this challenging disease. FUNDING: None.
引用
- Zhang L, Hall M, Lam SK, et al. Comparison of long-term survival with continued medical therapy, vagus nerve stimulation, and cranial epilepsy surgery in paediatric patients with drug-resistant epilepsy in the USA: an observational cohort study. Lancet Child Adolesc Health. 2023. PMID: 37276875. doi:10.1016/S2352-4642(23)00082-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。